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See related research by Perez et al., http://breast-cancer-research.com/content/16/3/R50I have read with great interest the article by Edith Perez
and colleagues reporting a correlation between trastuzu-
mab–emtansine (T-DM1) efficacy and human epidermal
receptor 2 (HER2) mRNA expression in the TDM4450g,
phase II randomized clinical trial [1]. While acknowledg-
ing that these results are merely hypothesis generating, I
believe some findings from this analysis deserve further
reasoning.
Upon central histopathological review, the proportion
of patients whose tumors had a normal HER2 status was
evenly distributed in the two arms of the trial (about
14%, see Table one in [1]). However, and not surprisingly,
these HER2-normal tumors clustered entirely in the low
HER2 mRNA group (Table two in [1]), where they ac-
counted for slightly less than one-third of the cases. At
the same time, the proportion of tumors with hormone
receptor expression was higher in the low HER2 mRNA
group (62.1% vs. 46.6%). These data indicate that, beyond
the number of HER2 receptors on the cell surface suitable
for T-DM1 binding, mRNA HER2 levels are also related
to different intrinsic biology and, possibly, reliance not
only on HER2 but also upon other regulatory pathways
such as hormone-receptor signaling [2].
In other terms, the efficacy of T-DM1 over docetaxel–
trastuzumab was compared in two biologically different
groups of patients, one of which was enriched with true
HER2-positive tumors, and the other being a mix of
HER2-negative and HER2-positive tumors at the lower
end of the spectrum to define HER2-positivity. I therefore
believe the extremely interesting finding of this analysis is
the comparable activity of T-DM1 and docetaxel–tras-
tuzumab in the low mRNA HER2 group, paralleled with
reduced toxicity. Indeed, a combined rate of response of
11% was reported in the TDM4258 and TDM437g phase
II trials in 36 heavily pretreated women whose tumor
turned out to be HER2 normal by central reanalysis [3,4].Correspondence: filippo.montemurro@ircc.it
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unless otherwise stated.Should an activity of T-DM1 comparable with that of
conventional chemotherapy be confirmed in tumors
with low HER2 expression, even in those not fulfilling
the conventional criteria for HER2 positivity, this would
translate into an increased number of patients benefiting
from this agent that, by virtue of its mechanism of action,
has shown to be excellently tolerated.
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